Edward Garon, MD
Enriched profileProfessor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA · David Geffen School of Medicine at UCLA
Edward Garon is Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA at David Geffen School of Medicine at UCLA. OpenAlex indexes 744 publications with 56,135 citations (h-index 77); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Edward Garon as a Highly Cited Researcher (Clinical Medicine, 2021-2025).
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Edward Garon, MD, is Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA. The public record shows 744 publications with 56,135 citations (h-index 77), centered on Lung Cancer (NSCLC/SCLC), Breast Cancer, Pancreatic Cancer. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 23 companies, 4 NIH-funded awards (2011–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Co-author
SITC clinical practice guideline informing immunotherapy standards of care for lung cancer and mesothelioma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Sponsor: A2 Biotherapeutics Inc.
- CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Sponsor: Jonsson Comprehensive Cancer Center
- Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
Sponsor: Dynavax Technologies Corporation
Industry payments
Updated 14 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202529 payments$54,874openpaymentsdata.cms.gov ↗
- Regeneron Pharmaceuticals, Inc.Program year202511 payments$14,853openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20252 payments$11,701openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
4 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
University of California Los Angeles
FY2026$623,462R01CA276917 - HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
University of California Los Angeles
FY2025$623,527R01CA276917 - HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
University of California Los Angeles
FY2025$225,068R01CA276917
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
Clinical cancer research
Clinical Trial2026 - Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test.
Proceedings of the National Academy of Sciences of the United States of America
Article2026 - Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis.
Nature communications
Erratum2026 - Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring After Therapy.
JCO oncology practice
Article2026
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/edward-garon-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
lungevity.org/news/media-releases/edward-garon-md-of-ucla-joins-lungevity-foundation-scientific-advisory-board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungevity.org ↗ - YouTube
youtube.com/uclajccc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - Doximity
Doximity professional profile (Oncology, Santa Monica, CA)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- BS
Biology, Massachusetts Institute of Technology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Editorial & leadership roles
journal and society appointments- Author
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmc.ncbi.nlm.nih.gov ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine20212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungevity.org ↗
- Director
Thoracic Oncology Program, Jonsson Comprehensive Cancer Center at UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Co-Director
Signal Transduction and Therapeutics research program, UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Attending physician
Ronald Reagan UCLA Medical Center and UCLA Santa Monica Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Recurring video/interview contributor
OncLive (clinical trial updates and expert perspectives in NSCLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Finn, MD
David Geffen School of Medicine at UCLA
Donald Tashkin, MD
David Geffen School of Medicine at UCLA
Aditya Bardia, MD
David Geffen School of Medicine at UCLA
Gottfried Konecny, MD
David Geffen School of Medicine at UCLA
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center